385,328 Shares of CVS Health Corporation $CVS Acquired by Mirae Asset Global Investments Co. Ltd.

Key Points

• Mirae Asset Global Investments acquired 385,328 CVS Health shares worth approximately $33.0 million during the third quarter. Institutional investors collectively own 80.66% of the company.
• CVS reported quarterly EPS of $2.58, exceeding estimates of $1.87, while revenue rose 7.3% year over year to $106.1 billion. The company provided fiscal 2026 EPS guidance of $7.90–$8.10.
• CVS declared a quarterly dividend of $0.665 per share, equivalent to an annualized $2.66 payout and a 2.9% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $109.64.

Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 385,328 shares of the pharmacy operator's stock, valued at approximately $33,019,000.

Other large investors have also bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of CVS Health during the 2nd quarter valued at approximately $12,747,462,000. State Street Corp grew its holdings in shares of CVS Health by 26.3% during the second quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator's stock worth $7,751,205,000 after purchasing an additional 15,604,883 shares in the last quarter. Wellington Management Group LLP grew its position in CVS Health by 49.8% in the second quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator's stock worth $3,496,725,000 after acquiring an additional 11,233,381 shares in the last quarter. Bank of America Corp DE increased its position in shares of CVS Health by 148.0% during the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator's stock valued at $2,398,868,000 after purchasing an additional 13,836,701 shares during the last quarter. Finally, Pzena Investment Management LLC bought a new stake in CVS Health in the 2nd quarter worth approximately $1,217,558,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Down 0.1%

CVS Health stock opened at $90.20 on Monday. The firm has a market cap of $115.36 billion, a price-to-earnings ratio of 23.86, a PEG ratio of 0.84 and a beta of 0.58. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The stock has a fifty day simple moving average of $91.22 and a two-hundred day simple moving average of $88.76. CVS Health Corporation has a 12 month low of $69.51 and a 12 month high of $110.68.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The business had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. During the same quarter in the previous year, the company posted $1.81 earnings per share. CVS Health's revenue for the quarter was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities analysts predict that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd will be given a dividend of $0.6650 per share. The ex-dividend date of this dividend is Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. CVS Health's dividend payout ratio is presently 70.37%.

Analysts Set New Price Targets

Several analysts have issued reports on the company. UBS Group reaffirmed a "buy" rating on shares of CVS Health in a research note on Tuesday, September 22nd. Sanford C. Bernstein reissued an "outperform" rating and set a $112.00 price target on shares of CVS Health in a research note on Wednesday, September 9th. Cantor Fitzgerald restated a "neutral" rating on shares of CVS Health in a report on Friday, October 9th. Wall Street Zen lowered shares of CVS Health from a "strong-buy" rating to a "buy" rating in a report on Monday, October 19th. Finally, Weiss Ratings lowered shares of CVS Health from a "buy (b-)" rating to a "hold (c+)" rating in a report on Friday, October 9th. Nineteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, CVS Health has an average rating of "Moderate Buy" and an average price target of $109.64.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: One valuation analysis says CVS could be approximately 27% undervalued, with the next earnings report providing a potential catalyst. Analysts reportedly expect quarterly earnings of about $1.62 per share, making segment performance and management commentary important for the shares. CVS Health Could Be 27% Undervalued As Earnings Focus Sharpens
• Positive Sentiment: CVS’s free Project Health screenings, which do not require appointments or insurance, support the company’s community-health strategy and could strengthen patient engagement and brand visibility. The immediate financial impact is likely limited. CVS Health Project Health Screenings
• Neutral Sentiment: Articles highlight CVS’s broader strategy of combining healthcare services with housing and other social-support initiatives. The approach may improve long-term outcomes and customer retention, but near-term earnings effects are unclear. CVS Health Beyond Housing
• Neutral Sentiment: Analyst-estimate and ratings coverage provides context ahead of earnings but does not identify a clear change in consensus or a new company-specific catalyst. CVS Health Stock Analyst Estimates and Ratings
• Negative Sentiment: The University of Kentucky and five other hospital systems are suing CVS over alleged fraud or prescription-contract breaches. The claims, including a reported $41 million UK lawsuit, create litigation, reimbursement, and reputational risks, although the allegations have not been proven. Hospital Systems Sue CVS UK Sues CVS Health
• Negative Sentiment: CVS reportedly faces as much as $2 billion of Medicare ratings-related risk. Any reduction in Medicare Advantage star ratings could hurt bonus payments, membership economics, and expectations for future earnings. CVS Health Medicare Ratings Risk

About CVS Health

CVS Health Corporation NYSE: CVS is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company's Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.